Please note that this website will be undergoing technical maintenance between 28 and 31 August. Consequently, users may experience instabilities and limited functionality. We apologise for the inconvenience.
For a better user experience please update your browser or use Chrome or Firefox browser.
Utilities
Publication detail
Home
Case T-103/17: Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG) (EU trade mark — Opposition proceedings — Application for EU word mark NORMOSANG — Earlier national word mark NORMON — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) — Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430))
Case T-103/17: Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG) (EU trade mark — Opposition proceedings — Application for EU word mark NORMOSANG — Earlier national word mark NORMON — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) — Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430))
Publication metadata
- Published:
- Corporate author(s): General Court (Court of Justice of the European Union)
- Subject: EU trade mark , pharmaceutical product , registered trademark , trademark law
- OJ : JOC_2018_142_R_0065
- CELEX : 62017TA0103
- IMMC : ARR-T-0103-2017
Document viewer
Note:
The publication cannot be displayed in the document viewer. Open web version
You may access it from: Download and languages